Mediwound Stock

Mediwound FCF Yield

The Free Cash Flow Yield of Mediwound (MDWD) as of Aug 7, 2026 is -9.04 %. In the previous year, Free Cash Flow Yield was -8.98 % — a change of 0.69% (lower).

FCF Yield

-9.04 %

YoY

0.69%

Last updated:

Free Cash Flow Yield of Mediwound is 2026 -9.04 % . Free Cash Flow Yield of Mediwound was 2025 -8.98 % . It decreases by 0.69% lower compared to the previous year.
Access this data via the Eulerpool API

Mediwound Stock analysis

What does Mediwound do? Mediwound Ltd is an Israeli company specializing in the development and marketing of therapies for chronic and acute wounds. The company was founded in 2000 and is headquartered in Yavne, Israel. Its history began with the idea of developing an innovative treatment method for burns. The company collaborated closely with the Israeli Ministry of Defense to find a better method for wound treatment. The result was the product NexoBrid, an enzymatic debridement treatment that aims to remove dead tissue from burn wounds to enable faster healing. Mediwound's business model is to develop and market innovative drugs and therapy solutions for wounds. The company operates in several areas, including burn wounds, chronic wounds, and trauma wounds. In the burn wounds sector, Mediwound offers the product NexoBrid, which enzymatically removes dead tissue from burns and eliminates neurotoxic substances that can damage wound healing if left in the tissue for too long. NexoBrid is already approved in several countries, including the USA and European countries. In the chronic wounds sector, Mediwound offers the product EscharEx, which is used to treat chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. EscharEx also uses an enzymatic approach and aims to remove dead tissue to enable the body's natural healing process. There are plans to launch EscharEx in Europe in the second half of 2021. Mediwound also operates in the trauma wounds sector and received the product MWPC003 in Europe in 2020. It is a novel enzymatic debriding product that can be used in the integrated therapy of complex trauma wounds with additional topical treatment options. Through the development of innovative therapies and drugs, Mediwound has established itself as a reliable partner in wound treatment. The company continues to focus on innovation and plans to expand its product range in the future. Overall, Mediwound Ltd is a groundbreaking company in the field of wound care. The company's products and solutions contribute to faster and more effective wound healing, improving the lives of patients worldwide. Mediwound is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mediwound stock

Free Cash Flow Yield of Mediwound is -9.04 % in 2026.

Free Cash Flow Yield of Mediwound changed from -8.98 % to -9.04 %, representing a 0.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Mediwound since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Mediwound with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Mediwound

All Key Metrics — Mediwound